Sarepta Therapeutics (SRPT) Granted FDA Accelerated Approval for Eteplirsen
Tweet
Share
E-mail
Get Alerts SRPT Hot Sheet
Join SI Premium – FREE
Sarepta Therapeutics (NASDAQ: SRPT) surges higher on FDA approval for eteplirsen
Letter from FDA
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wolfe Research Upgrades Sarepta Therapeutics (SRPT) to Outperform
- MBX Biosciences names new CEO and CFO amid leadership shift
- Sarepta Therapeutics (SRPT) PT Lowered to $20 at Piper Sandler
Create E-mail Alert Related Categories
FDA, Hot FDA News, Management Changes, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
